Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind placebo-controlled study of telitacicept in generalized myasthenia gravis with open-label extension
CTR20262341Phase 3Active
- Sponsor
- Vor Bio
- Start
- Apr 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in myasthenia gravis (MG) comparing Telitacicept with Placebo (2 arms). Started Apr 2026; status: active.
02
Drugs
telitacicept
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on CTR20262341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262341.